Stealth biotech Stipple bets on secretive ADCs
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Stipple, a biotech company, is focusing its efforts on developing secretive Antibody-Drug Conjugates (ADCs).
- The Readout discusses the prevalent issue of 'thin science' contributing to the hype surrounding peptides within the biotech sector.
- Proposed NIH budget cuts are generating blowback and concern within the biotech and research communities.
Why it matters: The NIH budget cuts could impact funding for critical early-stage drug development, including ADC research.
Ask SkimNews
